Patent: 10,039,758

Summary for Patent: 10,039,758

Title:	Compositions and methods for inhibiting bacterial and viral pathogens
Abstract:	Compositions and methods including Amodiaquine (AQ) or N-Desethy Amodiaquine (DEAQ) are provided for treating, inhibiting, or preventing cathepsin B dependent pathogens and toxins in a host cell or infected subject. Compositions and methods also include AQ or DEAQ in combination with an antibiotic for more effective clearance of the pathogen and/or toxins.
Inventor(s):	Martchenko; Mikhail (Claremont, CA), Zilbermintz; Leeor (Encino, CA), Leonardi; William (Rosemead, CA)
Assignee:	Keck Graduate Institute of Applied Life Sciences (Claremont, CA)
Application Number:	14/922,114
Patent Claims:	see list of patent claims

US Patent 10,039,758: Anthrax Inhibition via Amodiaquine (AQ) or N-Desethyl Amodiaquine (DEAQ) and Antibiotic Combinations

What does US 10,039,758 claim, at a technical level?

US 10,039,758 is directed to a treatment method that uses amodiaquine (AQ) or N-desethyl amodiaquine (DEAQ) to inhibit Bacillus anthracis in a host cell or in a subject, alone or with an antibiotic.

Independent claim 1 (core scope)

• A method of inhibiting B. anthracis in a host cell or a subject by administering AQ or DEAQ.

Claim 1 establishes:

• The target organism is specific (B. anthracis).
• The mechanism is framed as inhibition via dosing AQ/DEAQ.
• The route and dosage form are not stated in claim 1, leaving those to dependent claims or specification.

Key dependent claim constraints

Claim	Additional limitation	Practical meaning for enforceability
2	AQ/DEAQ dose: about 4.2–70 µM or about 1.5–10.0 mg/kg	Narrows claim coverage to dosing ranges likely tied to examples or in vitro potency
3	Further administering an antibiotic	Moves coverage from monotherapy to combination therapy
4	Antibiotic is selected from a defined list	Limits the “combination” axis to enumerated antibiotics and combinations
5	Antibiotic comprises Octodrine	Narrows claim set to Octodrine-containing regimens
6	AQ/DEAQ and antibiotic administered as a mixture	Requires co-formulation or co-administration as a mixture (impacts infringement theories)
7	AQ/DEAQ dose 1.5–10.0 mg/kg and Octodrine dose 1.5–50 mg/kg	Tightens dosing windows for Octodrine combinations

How broad is the claim set versus prior art risk?

The claim set has two distinct layers of breadth:

1. Broad active ingredient frame

   • “Amodiaquine or N-desethyl amodiaquine” is a narrow chemical genus (two specific entities).
   • But it is broad in therapeutic posture: inhibiting B. anthracis in cells or subjects.

2. Moderate to narrow combination frame

   • When combinations are used, the antibiotic must come from a list in claim 4, and the Octodrine variant is separately claimed.
   • Claim 6 adds “mixture,” which reduces functional ambiguity but also narrows ways competitors can design around.

Critical enforcement implication:
Even if AQ/DEAQ ant-infective activity was known generally, enforceability against anthrax-specific uses depends heavily on whether prior art discloses (i) AQ/DEAQ for B. anthracis inhibition and/or (ii) combination regimens with the listed antibiotics, especially Octodrine, within the recited dosing ranges.

What does the dosage language imply about novelty and written-description tethering?

Claim 2 and claim 7 include quantitative windows that are commonly tied to:

• in vitro concentration-response data for AQ/DEAQ (µM range), and
• in vivo exposure or administered dose in mg/kg (animal models or inferred clinical dosing).

Dose windows (as recited)

• AQ/DEAQ (claim 2):
  • about 4.2–70 µM (cell-context) OR
  • about 1.5–10.0 mg/kg (subject-context)
• Octodrine (claim 7):
  • about 1.5–50 mg/kg (subject-context)

Why this matters

Quantitative claim limitations often act as:

• a defensive narrowing tool against prior art,
• a disclosure-demand signal for the patentee to have exemplified these ranges.

From a freedom-to-operate perspective, these ranges are also the most reliable design-around knobs:

• Use AQ/DEAQ at outside the claimed dose window (if the regimen remains efficacious).
• Avoid “mixture” administration if combination therapy is needed (e.g., separate administrations).

Where is the patent likely strongest? (claim elements that are harder to find in prior art)

The highest-likelihood “novelty anchors” are:

1. Anthrax-specific use

   • “Inhibiting Bacillus anthracis” is explicit and organism-specific.

2. Use of DEAQ

   • Many prior art antimalarials focus on parent compounds; inclusion of N-desethyl amodiaquine may increase differentiation.

3. Octodrine combination and mixture requirement

   • Claim 5 and claim 7 are tied to Octodrine, and claim 6 requires administration as a mixture.

These elements are narrower than general reuse of antimalarials as antimicrobials, and narrower combinations typically increase defensibility.

Where is the patent most vulnerable? (claim elements that are more likely disclosed)

The risk concentrates around three points:

1. Repurposing a known drug for an explicit pathogen

   • AQ is a known antimalarial with biological activity, and repurposing against bacteria is a common prior-art theme.
   • If prior art includes broad “inhibits bacterial growth” for related organisms, examiners and challengers may argue obviousness for anthrax.

2. Dose range breadth

   • The ranges appear wide (e.g., 4.2–70 µM; 1.5–10 mg/kg). Wide ranges can be attacked if prior art discloses close or overlapping ranges.

3. Combination therapy with broadly used antibiotics

   • Claim 4 lists many antibiotics, many of which are common in bacterial infection regimens.
   • If prior art shows AQ/DEAQ can be combined with antibiotics generally, claim 3-4 may be vulnerable unless the patentee also shows nonobvious synergy or a specific rationale.

What is the patent landscape logic for AQ/DEAQ antianthrax?

Even without text-level verification of every citation, the landscape typically follows a repeatable pattern in repurposing patents:

• General antimicrobial activity of AQ/DEAQ against pathogens (or in macrophage-like models) is found first.
• Specific pathogen framing (here, B. anthracis) is added next to differentiate.
• Combination therapy appears as either:
  • a clinical translation move, or
  • an obvious extension of multi-drug anthrax management concepts.

For US 10,039,758, the most business-relevant landscape question is whether competitors can credibly claim they are operating outside:

• organism framing (different Bacillus target),
• compound frame (avoid AQ/DEAQ),
• dosage ranges,
• mixture requirement.

How do the claims map to likely commercial development routes?

1) AQ/DEAQ monotherapy strategy

• Covers direct inhibition using AQ/DEAQ (claim 1) with the dose limitations only if claim 2 is asserted.

Design-around potential:

• Use different dosing that stays outside 1.5–10 mg/kg and outside 4.2–70 µM.
• Use formulations that change effective exposure (even if mg/kg differs).

2) Combination therapy strategy using listed antibiotics

• Claim 3 and 4 cover adding any antibiotic from the enumerated list.

Design-around potential:

• Use an antibiotic not in the list.
• Use antibiotic(s) in a regimen that does not meet “administered as a mixture” for claim 6 (if that claim is the asserted one).

3) Octodrine-specific strategy

• Claim 5-7 form a dedicated sub-scope:
  • antibiotic comprises Octodrine,
  • and AQ/DEAQ plus Octodrine are administered as a mixture in claim 6 (and dose windows in claim 7).

Design-around potential:

• Avoid Octodrine entirely.
• Avoid mixing (administer separate dosage forms/time).
• Use different dose window(s) for either AQ/DEAQ or Octodrine.

What is the strongest litigation posture implied by the claim set?

A patentee’s strongest path typically combines:

• Claim 1 for broad coverage: AQ/DEAQ inhibition of B. anthracis in a host cell or subject.
• Claim 2 to constrain to specific effective doses.
• Claims 3-4 to lock in combination therapy choices.
• Claims 5-7 to narrow enforcement to a specific competitor-style regimen (Octodrine combinations, mixed administration, and dose windows).

If a defendant uses Octodrine and provides combination dosing within the windows, claim 6 and claim 7 can become high-leverage.

Key takeaways

• US 10,039,758 claims Bacillus anthracis inhibition using amodiaquine (AQ) or N-desethyl amodiaquine (DEAQ), with explicit dose windows in claims 2 and 7.
• Enforcement leverage increases when accused regimens use Octodrine and administer AQ/DEAQ as a mixture with dose ranges aligned to the patent.
• Primary vulnerability is obviousness risk for anthrax-specific use if prior art discloses bacterial inhibition by AQ/DEAQ more generally and if the claimed dose ranges overlap earlier disclosures.
• Most practical design-arounds are outside the recited AQ/DEAQ and/or Octodrine dose windows, use of antibiotics not enumerated in claim 4, and avoiding “mixture” administration (separate dosing rather than a mixture).

FAQs

1. Does claim 1 cover both in vitro (host cell) and in vivo (subject) uses?
   Yes. Claim 1 explicitly covers inhibition “in a host cell or in a subject.”

2. Are dosing constraints mandatory for infringement across the entire claim set?
   Dose limitations appear in claim 2 (AQ/DEAQ) and claim 7 (AQ/DEAQ plus Octodrine). Claim 1 alone does not state a dose.

3. Can a competitor combine AQ/DEAQ with any antibiotic?
   Not for claims 3 and 4. The antibiotic must be selected from the specific list in claim 4.

4. Is Octodrine a required element to fall within claims 5-7?
   Yes. Claims 5 and 7 require the antibiotic to comprise Octodrine.

5. What does “administered as a mixture” practically limit?
   It limits coverage where AQ/DEAQ and the antibiotic are administered as a mixture, which often maps to co-formulation or a single mixed composition rather than separate administrations.

References

1. United States Patent. US 10,039,758. (Claims excerpt as provided in prompt).

Details for Patent 10,039,758

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	November 12, 1998		2035-10-23